Literature DB >> 1691063

A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis.

R Verheijen1, F Van den Hoogen, R Beijer, A Richter, E Penner, W J Habets, W J van Venrooij.   

Abstract

We report the expression of a cDNA clone encoding 695 carboxyl-terminal amino acids of human DNA topoisomerase I (topoI) in Escherichia coli. More than 96% of the anti-HeLa topoI-positive sera from patients with a connective tissue disease displayed also an immunoreactivity with this recombinant protein (the HTopoA protein). Sera from patients with a definite diagnosis systemic sclerosis and reacting with HeLa topoI, all reacted with the HTopoA protein as well. Sera from patients with systemic sclerosis that did not contain anti-topoI antibodies (about 30% of the systemic sclerosis sera), as concluded from HeLa immunoblot, displayed also no immunoreactivity with our recombinant antigen. By expressing different fragments of HTopoA, we were able to assign at least three different autoimmune epitope regions on the HTopoA protein and we show that over a period of 5 years the amount of anti-topoI antibodies against these regions may fluctuate.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691063      PMCID: PMC1535233          DOI: 10.1111/j.1365-2249.1990.tb06438.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

Review 1.  Biochemical basis for the interactions of type I and type II topoisomerases with DNA.

Authors:  N Osheroff
Journal:  Pharmacol Ther       Date:  1989       Impact factor: 12.310

2.  Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I.

Authors:  H H Guldner; C Szostecki; H P Vosberg; H J Lakomek; E Penner; F A Bautz
Journal:  Chromosoma       Date:  1986       Impact factor: 4.316

3.  Monoclonal antibodies neutralizing mammalian DNA topoisomerase I activity.

Authors:  P Oddou; U Schmidt; R Knippers; A Richter
Journal:  Eur J Biochem       Date:  1988-11-15

4.  Scl-86, a marker antigen for diffuse scleroderma.

Authors:  W J van Venrooij; S O Stapel; H Houben; W J Habets; C G Kallenberg; E Penner; L B van de Putte
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

5.  Scl-70 antigen stability and its effect on antibody detection in scleroderma.

Authors:  V Kumar; C Kowalewski; M Koelle; S Qutaishat; T P Chorzelski; E H Beutner; M Jarzabek-Chorzelska; Z Kolacinska; S Jablonska
Journal:  J Rheumatol       Date:  1988-10       Impact factor: 4.666

6.  Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I.

Authors:  R M Lynn; M A Bjornsti; P R Caron; J C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

7.  Scl 70 antibody--a specific marker of systemic sclerosis.

Authors:  M Jarzabek-Chorzelska; M Blaszczyk; S Jablonska; T Chorzelski; V Kumar; E H Beutner
Journal:  Br J Dermatol       Date:  1986-10       Impact factor: 9.302

8.  Analysis of a cDNA clone expressing a human autoimmune antigen: full-length sequence of the U2 small nuclear RNA-associated B" antigen.

Authors:  W J Habets; P T Sillekens; M H Hoet; J A Schalken; A J Roebroek; J A Leunissen; W J van de Ven; W J van Venrooij
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

9.  Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA.

Authors:  S J Brill; S DiNardo; K Voelkel-Meiman; R Sternglanz
Journal:  Nature       Date:  1987 Mar 26-Apr 1       Impact factor: 49.962

10.  Isolation of type I and II DNA topoisomerase mutants from fission yeast: single and double mutants show different phenotypes in cell growth and chromatin organization.

Authors:  T Uemura; M Yanagida
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

View more
  10 in total

Review 1.  B-cell epitopes of scleroderma-specific autoantigens.

Authors:  R Verheijen
Journal:  Mol Biol Rep       Date:  1992-06       Impact factor: 2.316

2.  IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors:  Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

3.  Rebound of anti-topoisomerase I antibody titres after plasma exchange.

Authors:  F H Van den Hoogen; A M Boerbooms; L B Van de Putte; R Verheijen; W Van Venrooij; A J Croockewit
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

Review 4.  Antitopoisomerase and anticentromere antibodies in the sclerodermatosus complex.

Authors:  C G Kallenberg
Journal:  Clin Rev Allergy       Date:  1994

5.  Molecular cloning of a major CENP-B epitope and its use for the detection of anticentromere autoantibodies.

Authors:  R Verheijen; B A de Jong; E H Oberyé; W J van Venrooij
Journal:  Mol Biol Rep       Date:  1992-02       Impact factor: 2.316

6.  The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).

Authors:  M Kuwana; J Kaburaki; Y Okano; H Inoko; K Tsuji
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

7.  A recombinant topoisomerase I ELISA: screening for IgG, IgM and IgA anti-topo I autoantibodies in human sera.

Authors:  R Verheijen; B A de Jong; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

8.  Multiple-antigen immunization of chickens facilitates the generation of recombinant antibodies to autoantigens.

Authors:  D Hof; M O Hoeke; J M H Raats
Journal:  Clin Exp Immunol       Date:  2007-12-06       Impact factor: 4.330

9.  Analysis of an immunodominant epitope of topoisomerase I in patients with systemic sclerosis.

Authors:  T M Meesters; M Hoet; F H van den Hoogen; R Verheijen; W J Habets; W J van Venrooij
Journal:  Mol Biol Rep       Date:  1992-05       Impact factor: 2.316

10.  Detection of anti-topoisomerase I antibodies using a full length human topoisomerase I recombinant protein purified from a baculovirus expression system.

Authors:  J Whyte; W C Earnshaw; J J Champoux; L H Parker; L Stewart; N D Hall; N J McHugh
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.